Bringing the future of medical technology to the point of care.
Bioptive partners with clinicians, hospitals and pharmacies across our territories to deploy breakthrough AI-powered healthcare technologies, starting with Cardisio, our flagship cardiac-screening platform.
A medical-technology distributor built for the AI era of healthcare.
Bioptive Ltd, headquartered in Nicosia and operating across the Eastern Mediterranean, the Gulf and South Asia, identifies, in-licenses and deploys next-generation medical technologies, with a focus on AI-enabled diagnostics that move clinical decision-making closer to the patient.
We partner with physicians, hospitals, medical diagnostic centers and pharmacies to bring the next generation of healthcare technology to the point of care. Cardisio, the world's first commercial 3D AI cardiac-screening platform, is the first product in our portfolio.
Cardisio is the first product Bioptive brings to market: a CE-certified AI cardiac-screening platform developed by Cardisio GmbH in Frankfurt. More AI medical technologies are on the way.
Why rely on 100-year-old technology?
The standard ECG was patented in 1924. Cardisiography is the first commercial cardiac screening tool to combine 3D vectorcardiography, signal optimization and deep learning, delivering an accuracy and breadth of detection that the legacy 2D ECG simply cannot match.
- 2D recording, <45% sensitivity
- Limited electrical signal information
- Used mainly for arrhythmia diagnosis
- Full 360° 3D analysis of the heart's electrical excitation
- 3.2 million features per measurement
- Detects CAD, structural heart disease & arrhythmia
Three pathways. One screening test.
Coronary Artery Disease
Clogged arteries impede blood flow. Most common cardiac condition, and historically the most difficult to detect non-invasively.
Structural Heart Disease
Abnormalities in the heart's structure. Usually acquired via infection or prolonged strain, often only detected once damage has occurred.
Heart Arrhythmia
Flaws in the heart's electrical rhythm. Twelve types, many of them notoriously hard to capture, with conventional ECG accuracy near 40%.
From recording to result in about fifteen minutes.
Signal recording
Five electrodes are placed on the patient's torso, similar to an ECG. They rest still while the device captures the heart's full 3D electrical activity.
Cloud AI analysis
Recordings are streamed to the Cardisio cloud, where proprietary AI processes 3.2 million features and 290 parameters per measurement.
Medical consultation
A web-based CSG report is delivered to the medical professional in real time. They discuss findings with the patient and initiate next steps.
Billions of bio-parameters, continuously learning.
Cardisio's models are trained on one of the world's largest cardiac signal repositories. Every measurement strengthens the platform, improving sensitivity and unlocking new clinical applications.
Exclusive distribution across four strategic territories.
Greece
Bahrain
Saudi Arabia
India
Everything you need to know about working with Bioptive.
What is Cardisiography and how does it differ from a standard ECG?
How long does a single screening take?
Which conditions can Cardisiography detect?
Is the technology clinically validated and CE-marked?
Who uses Cardisiography in practice?
How does a clinic or hospital partner with Bioptive?
Where is Bioptive headquartered and where do you operate?
Bringing breakthrough cardiac care to your clinic, hospital or network.
Whether you're a healthcare provider, an institutional partner or a journalist, we'd be delighted to hear from you.
1082 Nicosia, Cyprus